中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
11期
11-13
,共3页
肺腺癌%白桦丹醌%破骨细胞%迁移%骨转移
肺腺癌%白樺丹醌%破骨細胞%遷移%骨轉移
폐선암%백화단곤%파골세포%천이%골전이
Lung adenocarcinoma%Plumbagin%Osteoclast%Migration%Bone metastasis
目的：研究白桦丹醌在抗人类肺腺癌细胞系PC9骨转移中的作用。方法：采用左心室注射稳转荧光素酶的PC9细胞构建肺癌骨转移动物模型，研究白桦丹醌对PC9骨转移的抑制作用；采用SRB研究白桦丹醌对PC9的毒性作用，采用transwell迁移实验检测其对PC9体外迁移的抑制作用；采用PC9与Raw264.7共培养构建肺癌诱导破骨形成并用白桦丹醌处理，研究白桦丹醌对PC9诱导形成破骨细的抑制作用。结果：动物实验显示，心室注射PC9细胞40 d后，对照组5只裸鼠均出现明显转移，而用药组虽然也出现4只裸鼠转移，但用药组转移灶的光子值（2759200±2670290）显著小于对照组（8732800±6191628）（P<0.05）。SRB显示2μM白桦丹醌对PC9无明显杀伤作用，但可显著抑制PC9的迁移能力及显著抑制PC9诱导的破骨细胞形成，组间比较差异均有统计学意义（P<0.05）。结论：白桦丹醌可通过抑制PC9迁移及抑制PC9诱导的破骨细胞形成的方式抑制PC9骨转移，显示其作为抗肺癌骨转移药物的应用前景。
目的：研究白樺丹醌在抗人類肺腺癌細胞繫PC9骨轉移中的作用。方法：採用左心室註射穩轉熒光素酶的PC9細胞構建肺癌骨轉移動物模型，研究白樺丹醌對PC9骨轉移的抑製作用；採用SRB研究白樺丹醌對PC9的毒性作用，採用transwell遷移實驗檢測其對PC9體外遷移的抑製作用；採用PC9與Raw264.7共培養構建肺癌誘導破骨形成併用白樺丹醌處理，研究白樺丹醌對PC9誘導形成破骨細的抑製作用。結果：動物實驗顯示，心室註射PC9細胞40 d後，對照組5隻裸鼠均齣現明顯轉移，而用藥組雖然也齣現4隻裸鼠轉移，但用藥組轉移竈的光子值（2759200±2670290）顯著小于對照組（8732800±6191628）（P<0.05）。SRB顯示2μM白樺丹醌對PC9無明顯殺傷作用，但可顯著抑製PC9的遷移能力及顯著抑製PC9誘導的破骨細胞形成，組間比較差異均有統計學意義（P<0.05）。結論：白樺丹醌可通過抑製PC9遷移及抑製PC9誘導的破骨細胞形成的方式抑製PC9骨轉移，顯示其作為抗肺癌骨轉移藥物的應用前景。
목적：연구백화단곤재항인류폐선암세포계PC9골전이중적작용。방법：채용좌심실주사은전형광소매적PC9세포구건폐암골전이동물모형，연구백화단곤대PC9골전이적억제작용；채용SRB연구백화단곤대PC9적독성작용，채용transwell천이실험검측기대PC9체외천이적억제작용；채용PC9여Raw264.7공배양구건폐암유도파골형성병용백화단곤처리，연구백화단곤대PC9유도형성파골세적억제작용。결과：동물실험현시，심실주사PC9세포40 d후，대조조5지라서균출현명현전이，이용약조수연야출현4지라서전이，단용약조전이조적광자치（2759200±2670290）현저소우대조조（8732800±6191628）（P<0.05）。SRB현시2μM백화단곤대PC9무명현살상작용，단가현저억제PC9적천이능력급현저억제PC9유도적파골세포형성，조간비교차이균유통계학의의（P<0.05）。결론：백화단곤가통과억제PC9천이급억제PC9유도적파골세포형성적방식억제PC9골전이，현시기작위항폐암골전이약물적응용전경。
Objective:To investigate the effects of plumbagin on lung cancer bone metastasis. Method:Left ventricles injection of PC9 cells stably expressing luciferase was used to establish lung cancer bone metastasis model and the bone metastatic lesions were monitored by bioluminescent imaging and X-ray. The inhibiting effect against migration ability was detected by transwell assay and SRB test was applied to evaluated the inhibiting effects of proliferation. The coculture system of PC9 cells and Raw264.7 cells were preformed to establish the PC9 induced-osteoclast differentiation assay. The indicated concentrations of plumbagin were administrated to animals or PC9 cells.Result:In mouse model of bone metastasis, we demonstrated that plumbagin significantly repressed breast cancer cell metastasis and osteolysis. Mean photons emission of plumbagin group(2 759 200±2 670 290)were significantly lower than control group(8 732 800±6 191 628)(P<0.05) 40 day after PC9 cells injection. In vitro experimentations showed 2μM Plumbagin significantly inhibited the migration of PC9 cells and osetoclasts formation induced by PC9 cells,but did not influence the proliferation of PC9 cells. Conclusion:Plumbagin has displayed the powerful anti bone metastasis effects against PC9 cell line and it might work via inhibiting cancer cell migration and cancer cell induced osteoclastogenesis,suggesting that Plumbagin could be a potential candidate in the treatment of breast cancer cell bone metastasis.
